Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Innovative Industrial Properties Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Innovative Industrial Properties Inc trades at $64.44 (market cap $1.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 21.3× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.79% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | IIPR | |
|---|---|---|
Market Cap | $39.89B | $1.87B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $64.44 |
52-Week Low | $278.09 | $44.58 |
Enterprise Value | $38.15B | $2.25B |
Dividend Yield | — | 11.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IIPR trades at $64.44, up 2.16% with a bullish technical signal from moving averages. The REIT shows strong profitability with 45.58% net margins and stable quarterly earnings beats. Recent developments include successful debt refinancing and a $1.90 quarterly dividend declaration. Valuation appears reasonable with P/E of 16.44 and P/B of 1.05, though revenue declined to $266M in 2025.
Outlook remains positive with cannabis rescheduling progress and improved capital structure, but risks include tenant credit quality and sector volatility. The 13.32% dividend yield offers income appeal, though coverage requires monitoring. Analyst consensus leans cautious with 36% buy ratings amid revenue pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
